Sanofi India gets nod to transfer Nutraceuticals business to Universal Nutriscience

28 Jul 2021 Evaluate

Sanofi India’s board has approved a transaction for the slump sale and transfer of the company’s Nutraceuticals business, on a going concern basis to Universal Nutriscience for a consideration of Rs 5,870 million including debt like obligations (such as retirals and provision for sales returns), subject to customary working capital adjustments and post-closing adjustment in connection with certain contractual arrangements between the parties. Completion of the transaction is anticipated within the next 3 months, subject to fulfillment of conditions as set out in the Business Transfer Agreement.

The Nutraceuticals business of the company comprises 16 brands and 30 SKUs. These along with related business assets and liabilities including contracts, intellectual property rights, inventory, and all employees associated with this business will transition to Universal Nutriscience. This decision will help the Company to invest and focus on its strategic growth pillars, while allowing the Nutraceuticals business and the people associated with it, to significantly benefit in a company specialized in Nutraceuticals and Wellness. The Board of Directors of the company at its meeting held on July 27, 2021 has approved the same.

Sanofi India is a global biopharmaceutical company focused on human health. The company prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. The company stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

Sanofi India Share Price

4334.40 -37.30 (-0.85%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×